Exact Sciences Corporation

Exact Sciences Corporation is an American molecular diagnostics company headquartered in Madison, Wisconsin, specializing in the early detection and prevention of cancer, and guiding personalized treatment. Its mission is to eradicate cancer and the suffering it causes through tests that help prevent cancer, detect it earlier, and guide treatment.

The company's key product offerings include Cologuard, a non-invasive stool-based DNA test for colorectal cancer screening, and Oncotype DX, a suite of tissue-based genomic tests that inform personalized treatment decisions for breast and colon cancer. Exact Sciences also develops and offers other advanced diagnostic solutions such as OncoExTra for comprehensive genomic profiling, Oncodetect for molecular residual disease monitoring, Cancerguard for multi-cancer early detection, Riskguard for hereditary cancer risk assessment, and Oncoguard Liver test.

In a significant development, Abbott Laboratories completed its acquisition of Exact Sciences on March 23, 2026, in a deal valued at approximately $21 billion. As a result, Exact Sciences Corporation is now a wholly owned subsidiary of Abbott Laboratories, and its shares ceased trading on the Nasdaq Stock Market on March 20, 2026. This acquisition positions Abbott as a leader in the rapidly growing cancer screening and precision oncology diagnostics segments.